COMPANY

Aer Therapeutics

HQ: Research Triangle Park, NC source · aertherapeutics.com ↗

Keywords: obstructive lung disease inhaled chronic obstructive pulmonary disease asthma COPD Flexlamose AER-01

Location: Research Triangle Park, NC · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $3M in debt securities (Form D filed Aug 19, 2026). SEC Form D 0001959576-26-000001 (Aug 19, 2026)
Evidence (1 event)
- Aug 19, 2026 · SEC Form D 0001959576-26-000001
  Name of Issuer: Aer Therapeutics, Inc.; CIK: 1959576; Address: Research Triangle Park, NC; Submission type: D; Filing date: 2026-08-19; Industry Group: Biotechnology; Date of First Sale: 2026-08-07; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

2024-12 Trial start Phase 2: A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD source ↗
May 26, 2023 Trial start Phase 1: Single and Multiple Ascending Dose Study of AER-01 source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06731959	A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD	Phase 2	Not yet recruiting	2024-12	2025-11 (estimated)
NCT05862623	Single and Multiple Ascending Dose Study of AER-01	Phase 1	Unknown status (ClinicalTrials.gov)	May 26, 2023	2024-08 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗